• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Kronos Bio Inc.

    11/27/23 4:41:09 PM ET
    $KRON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KRON alert in real time by email
    SC 13D 1 ef20015453_sc13d.htm SC 13D
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No.  )*

    KRONOS BIO, INC.
    (Name of Issuer)

    Common Stock
    (Title of Class of Securities)

    50107A104
    (CUSIP Number)

    Norbert Bischofberger, Ph.D.
    1300 So. El Camino Real, Suite 400
    San Mateo, California 94402
    Telephone:  (650) 781-5200
     (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    November 15, 2023
    (Date of Event Which Requires Filing of This Statement)
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
     
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
     
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    CUSIP No. 50107A104
    1
    NAMES OF REPORTING PERSONS
     
     
    Norbert Bischofberger, Ph.D.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☒

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    PF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
    Not applicable
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Norbert Bischofberger, Ph.D.:  USA
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    5,199,243 (1)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    5,425,494 Shares (2)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    5,199,243 (1)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    5,425,494 Shares (2)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    10,624,737 Shares
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    17.4% (3)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    (1)          Includes 2,856,702 shares of common stock issuable within 60 days of the date of this report upon the vesting and settlement of restricted stock units and the exercise of stock options held by the Reporting Person.
     
    (2)          Includes (a) 4,370,494 shares of common stock beneficially owned by the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994, of which Dr. Bischofberger is a trustee, (b) 263,750 shares of common stock beneficially owned by Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020, of which Dr. Bischofberger is a trustee, (c) 263,750 shares of common stock beneficially owned by Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020, of which Dr. Bischofberger is a trustee, (d) 263,750 shares of common stock beneficially owned by Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020, of which Dr. Bischofberger is a trustee and (e) 263,750 shares of common stock beneficially owned by Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020, of which Dr. Bischofberger is a trustee.
     
    (3)          This percentage is calculated based on 58,316,520 shares of common stock outstanding as of November 8, 2023 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on November 13, 2023, plus 2,856,702 shares of common stock underlying the restricted stock units and options described in note (1) above in accordance with Rule 13d-3(d)(1) under the Exchange Act.
     

    Page 2


    CUSIP No. 50107A104
    1
    NAMES OF REPORTING PERSONS
     
     
    Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☒

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    PF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
    Not applicable
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    California
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    4,370,494 Shares
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    4,370,494 Shares
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    4,370,494 Shares
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.5% (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          This percentage is calculated based on 58,316,520 shares of common stock outstanding as of November 8, 2023 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on November 13, 2023
     

    Page 3


    CUSIP No. 50107A104
    1
    NAMES OF REPORTING PERSONS
     
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☒

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    PF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
    Not applicable
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    California
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    263,750 Shares
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    263,750 Shares
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    263,750 Shares
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.4% (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          This percentage is calculated based on 58,316,520 shares of common stock outstanding as of November 8, 2023 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on November 13, 2023
     

    Page 4


    CUSIP No. 50107A104
    1
    NAMES OF REPORTING PERSONS
     
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☒

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    PF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
    Not applicable
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    California
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    263,750 Shares
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    263,750 Shares
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    263,750 Shares
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.4% (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          This percentage is calculated based on 58,316,520 shares of common stock outstanding as of November 8, 2023 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on November 13, 2023
     

    Page 5


    CUSIP No. 50107A104
    1
    NAMES OF REPORTING PERSONS
     
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☒

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    PF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
    Not applicable
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    California
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    263,750 Shares
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    263,750 Shares
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    263,750 Shares
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.4% (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          This percentage is calculated based on 58,316,520 shares of common stock outstanding as of November 8, 2023 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on November 13, 2023
     

    Page 6


    CUSIP No. 50107A104
    1
    NAMES OF REPORTING PERSONS
     
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☒

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    PF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
    Not applicable
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    California
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    263,750 Shares
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    263,750 Shares
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    263,750 Shares
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.4% (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          This percentage is calculated based on 58,316,520 shares of common stock outstanding as of November 8, 2023 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on November 13, 2023
     

    Page 7


    Item 1.
    Security and Issuer.
     
    This Schedule 13D relates to the common stock, par value $0.001 per share (the “Common Stock”), of Kronos Bio, Inc. (the “Issuer”). The Issuer’s principal executive office is located at 1300 So. El Camino Real, Suite 400, San Mateo, California 94402.
     
    Item 2.
    Identity and Background

    (a)          Names of Persons Filing:
     
    Norbert Bischofberger, Ph.D.
     
    Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020
     
    (b)          Address of Principal Business Office, or, if none, Residence:

    The address of Norbert Bischofberger, Ph.D. is:
    c/o Kronos Bio, Inc.
    1300 So. El Camino Real, Suite 400
    San Mateo, California 94402

    The address of Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994:
    c/o Kronos Bio, Inc.
    1300 So. El Camino Real, Suite 400
    San Mateo, California 94402

    The address of Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020 is:
    c/o Kronos Bio, Inc.
    1300 So. El Camino Real, Suite 400
    San Mateo, California 94402


    Page 8


    The address of Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020 is:
    c/o Kronos Bio, Inc.
    1300 So. El Camino Real, Suite 400
    San Mateo, California 94402

    The address of Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020 is:
    c/o Kronos Bio, Inc.
    1300 So. El Camino Real, Suite 400
    San Mateo, California 94402

    The address of Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger GST Non-Exempt Trust dated April 29, 2020 is:
    c/o Kronos Bio, Inc.
    1300 So. El Camino Real, Suite 400
    San Mateo, California 94402

    (c)          Present Principal Occupations of the Persons Filing:

    Norbert Bischofberger, Ph.D.: Chief Executive Officer and Director of the Issuer.

    Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994: Not Applicable

    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020: Not applicable

    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020: Not applicable

    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020: Not applicable

    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020: Not applicable

    (d)–(e)    During the last five years, Reporting Persons have not been (1) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (2) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding has been or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f)          Citizenship:
     
    Norbert Bischofberger, Ph.D.:  USA

    Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994:  California

    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020:  California

    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020:  California


    Page 9


    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020:  California

    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020:  California

    Item 3.
    Source and Amount of Funds or Other Consideration

    Reporting Persons are deemed to beneficially own shares of Common Stock of the Issuer as reflected in this Schedule 13D.  The consideration used to acquire beneficial ownership of the shares of Common Stock of the Issuer consisted solely of personal funds of Norbert Bischofberger, Ph.D.  Between November 15, 2023 and November 17, 2023, Dr. Bischofberger purchased an aggregate of 1,731,056 shares of Common Stock of the Issuer in the open market at purchase prices ranging from $0.765 to $1.12 per share (the “Shares”).  The purchase of the Shares resulted in the acquisition by the Reporting Persons of 2% or greater than the number of the Issuer’s outstanding Common stock, resulting in the loss of their eligibility to file on a Schedule 13G as an “Exempt Investor”.

    Item 4.
    Purpose of Transaction
     
    The information furnished in Item 3 is incorporated into this Item 4 by reference. The Reporting Persons acquired the Shares for investment purposes. There are no plans or proposals that would relate to any of the enumerated items in Item 4 of Schedule 13D, except Norbert W. Bischofberger may receive equity awards from the Issuer in the future as compensation for his service as the President and Chief Executive Officer of the Issuer.

    Item 5.
    Interest in Securities of the Issuer
     
    (a)(b)  The Filing Persons collectively beneficially own an aggregate of 10,624,737 shares of Common Stock, including an aggregate of 2,856,702 shares of common stock underlying restricted stock units and options which have vested or will vest within sixty (60) days of this Schedule 13D, representing 17.4% of the outstanding Common Stock of the Issuer, based on 58,316,520 shares outstanding plus the 2,856,702 shares of common stock underlying the foregoing restricted stock units and options in accordance with Rule 13d-3(d)(1) under the Exchange Act.  The following information with respect to the beneficial ownership of the Common Stock of the Issuer by the Filing Persons is provided as of the date of this filing:

    Reporting Person
     
    Shares Held
    Directly
       
    Sole
    Voting
    Power
       
    Shared
    Voting
    Power
       
    Sole
    Dispositive
    Power
       
    Shared
    Dispositive
    Power
       
    Beneficial
    Ownership
       
    Percentage
    of Class(1)
     
    Norbert Bischofberger,
    Ph.D.
       
    5,199,243
         
    5,199,243
         
    5,425,494
         
    5,199,243
         
    5,425,494
         
    10,624,737
         
    17.4%

                                                             
    Norbert W. & Inger A.
    Bischofberger Revocable
    Inter Vivos Trust, dtd
    August 29, 1994
       
    4,370,494
         
    4,370,494
         
    0
         
    4,370,494
         
    0
         
    4,370,494
         
    7.5%

                                                             
    Norbert W. Bischofberger
    and Inger A. Bischofberger,
    Trustees of the David
    Michael Anthony Dynasty
    GST Exempt Trust dated
    April 29, 2020
       
    263,750
         
    263,750
         
    0
         
    263,750
         
    0
         
    263,750
         
    0.4%

                                                             
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020
       
    263,750
         
    263,750
         
    0
         
    263,750
         
    0
         
    263,750
         
    0.4%

                                                             
    Norbert W. Bischofberger
    and Inger A. Bischofberger,
    Trustees of the Irene Alisha
    Bischofberger Dynasty GST
    Exempt Trust dated April
    29, 2020
       
    263,750
         
    263,750
         
    0
         
    263,750
         
    0
         
    263,750
         
    0.4%

                                                             
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020
       
    263,750
         
    263,750
         
    0
         
    263,750
         
    0
         
    263,750
         
    0.4%


    (c)  Other than the acquisition of the shares as reported herein, and as described under Item 4, the Reporting Persons have not affected any transactions in the shares of the Issuer during the past 60 days or since the most recent filing of Schedule 13D, whichever is less.

    (d)  To the best knowledge of Reporting Persons, no persons other than the Reporting Persons have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of the shares of common stock reported in Item 5(a).

    (e) Not applicable.


    Page 10


    Item 6.
    Contracts, Arrangements, Understandings Or Relationships With Respect To Securities Of The Issuer.
     
    The information furnished in Item 2 is incorporated into this Item 6 by reference.

    Item 7.
    Material To Be Filed As Exhibits.
     
    A.         Agreement regarding filing of joint Schedule 13D.


    Page 11


    Signature
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 27, 2023

     
     /s/ Norbert Bischofberger, Ph.D.
     
    Norbert Bischofberger, Ph.D.

     
    Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994
         
     
    By:
     /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee

     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020
         
     
    By:
     /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee

     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020
         
     
    By:
     /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee

     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020
         
     
    By:
     /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee

     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020
         
     
    By:
     /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee


    Page 12


    Exhibit A

    JOINT FILING STATEMENT
     
    I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the Common Stock of Kronos Bio, Inc. is filed on behalf of each of the undersigned.
     
    Dated: November 27, 2023

       
     
     /s/ Norbert Bischofberger, Ph.D.
     
    Norbert Bischofberger, Ph.D.

     
    Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994
         
     
    By:
     /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee

     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020
         
     
    By:
     /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee

     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020
         
     
    By:
     /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee

     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020
         
     
    By:
     /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee

     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020
         
     
    By:
     /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee



    Page 13


    Get the next $KRON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KRON

    DatePrice TargetRatingAnalyst
    11/14/2024$6.00 → $1.00Overweight → Neutral
    Piper Sandler
    11/14/2024Buy → Hold
    TD Cowen
    9/14/2022$12.00Buy
    Berenberg
    2/28/2022$50.00 → $30.00Overweight
    Piper Sandler
    11/10/2021$35.00 → $36.00Buy
    HC Wainwright & Co.
    10/20/2021Outperform
    Cowen
    6/24/2021$35.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $KRON
    SEC Filings

    See more
    • SEC Form SC 14D9 filed by Kronos Bio Inc.

      SC 14D9 - Kronos Bio, Inc. (0001741830) (Subject)

      5/15/25 1:09:14 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Kronos Bio Inc.

      10-Q - Kronos Bio, Inc. (0001741830) (Filer)

      5/8/25 4:21:04 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC14D9C filed by Kronos Bio Inc.

      SC14D9C - Kronos Bio, Inc. (0001741830) (Subject)

      5/1/25 9:22:44 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT & CEO Bischofberger Norbert W bought $733,801 worth of shares (615,518 units at $1.19) (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      7/1/24 8:27:32 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT & CEO Bischofberger Norbert W bought $3,119,081 worth of shares (3,005,122 units at $1.04) (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      6/12/24 7:23:55 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bischofberger Norbert W bought $1,470,395 worth of shares (1,731,056 units at $0.85), increasing direct ownership by 214% to 2,540,665 units (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      11/17/23 5:41:27 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kronos Bio Inc.

      SC 13G/A - Kronos Bio, Inc. (0001741830) (Subject)

      11/14/24 7:58:27 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Kronos Bio Inc.

      SC 13D/A - Kronos Bio, Inc. (0001741830) (Subject)

      7/2/24 9:01:03 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Kronos Bio Inc.

      SC 13D/A - Kronos Bio, Inc. (0001741830) (Subject)

      6/12/24 7:32:56 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (NASDAQ:KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ( "Concentra"), whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock ("Kronos Bio Common Stock"), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 50% of the net proceeds in the case of a disposition of the Company's product ca

      5/1/25 8:30:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results. Fourth Quarter and Full Year 2024 Financial Results Cash, cash equivalents and investments: Cash, cash equivalents and investments as of December 31, 2024, were $112.4 million.R&D Expenses: Research and development expenses were $8.4 million for the fourth quarter of 2024, which includes non-cash stock-based compensation expense of $0.7 million. For the full year of 2024, research and development expenses were $48.7 million, which includes non-cash stock-based compensation expense o

      3/18/25 4:01:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Announces CEO Transition and Reduction in Force

      – Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that its Board of Directors has appointed Deborah Knobelman, Ph.D., as President and Interim Chief Executive Officer, effective December 3, 2024. Dr. Knobelman will be the principal executive, financial and accounting officer. She is succeeding Norbert Bischofberger, Ph.D., who will step dow

      11/27/24 7:30:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Financials

    Live finance-specific insights

    See more

    $KRON
    Leadership Updates

    Live Leadership Updates

    See more

    $KRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $KRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

      Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manageable safety profile, with no grade 3/4 neutropenia, dose proportional exposure, dose-dependent target engagement, and 24-hour plasma half-life Dose escalation continues; dosing of patients at the 80 mg dose level is ongoing Enrollment ongoing in dose expansion phase in MYC-dependent and other transcriptionally addicted solid tumors, including lung, ovarian, and triple negative breast cancers Company to host conference call and webcast today at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D.

      10/13/23 12:30:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13

      SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will host a conference call and webcast on Friday, October 13, 2023, at 4:30 p.m. ET., followed by a Q&A session. The event will feature trial investigator, Miguel Villalona-Calero, M.D, Medical Oncologist and Director of Early Therapeutics, City of Hope, along with Kronos Bio management, who will discuss the current treatment landscape for patients with MYC-dependent solid tumors, provide an overview of KB-0742 and further discuss the poster to be presented at the AACR-NCI-EORTC Interna

      10/4/23 4:05:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

      Company to discontinue Phase 3 entospletinib trial for strategic reasons Enrollment continues for Phase 1/2b trial in relapsed/refractory AML with Kronos Bio's next generation SYK inhibitor, lanraplenib Company on track to provide KB-0742 update from ongoing Phase 1/2 clinical trial in Q4 With $270.3 million in cash, cash equivalents and investments as of Sept. 30, 2022, Kronos Bio extends expected cash runway from Q4 2024 into Q2 2025 Conference call and webcast scheduled for today at 4:30 p.m. ET SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today

      11/8/22 4:05:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Announces CEO Transition and Reduction in Force

      – Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that its Board of Directors has appointed Deborah Knobelman, Ph.D., as President and Interim Chief Executive Officer, effective December 3, 2024. Dr. Knobelman will be the principal executive, financial and accounting officer. She is succeeding Norbert Bischofberger, Ph.D., who will step dow

      11/27/24 7:30:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer

      SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy functions. "I'm excited to have Deb join our team. She is a proven life sciences leader, and her strategic vision will play a critical role in shaping the future of Kronos Bio. As we continue to

      5/21/24 8:15:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • SEC Form 4 filed by Chief Administrative Officer Frisbee Allison

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      10/15/24 6:57:17 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Lin Charles Y

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      10/15/24 6:55:36 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT & CEO Bischofberger Norbert W bought $733,801 worth of shares (615,518 units at $1.19) (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      7/1/24 8:27:32 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Kronos from Overweight to Neutral and set a new price target of $1.00 from $6.00 previously

      11/14/24 7:43:21 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos downgraded by TD Cowen

      TD Cowen downgraded Kronos from Buy to Hold

      11/14/24 7:42:59 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berenberg initiated coverage on Kronos with a new price target

      Berenberg initiated coverage of Kronos with a rating of Buy and set a new price target of $12.00

      9/14/22 7:25:57 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care